RE:RE:RE:RE:RE:RE:ConsolidationContrary to ours, that biotech is not listed on the stock exchange. If it ever uplists (IPO), it will be at a much higher price than our current TLT stock. So we'Re amazingly priviledged.
Solid tumor cancers command higher deals than blood cancers. That's a known fact in the oncology industry as solid tumor cancers are much more complicated to destroy. Blood disorders offer a much higher survival rate than solid tumor cancers.
Research article Economic Evaluations of Hematological Malignancies Compared withSolid Tumors The cost of a drug is measured in monetary units while benefit is measured in health gain such as survival. However, quality of life is added to this formula. Another way to compare the two treatments is to calculate the ICER. For that we will need to add the monetary effect of each treatment. For example, intervention A would cost $10,000 per year while intervention B would cost $5,000 per year. In the above example, ICER equals 10,000-5,000/2.5-1.75=$6,666.67 per QUALY for intervention A compared with intervention B. So all things being equal, any jv for the GBM indication (solid tumor) should command a higher upfront payment when compared to a blood cancer as the example below is also for a pre-clinical research.
Note also that it was not the first time that Celgene was working with that biotech.
_________________
Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada Jan. 29, 2019
The Big Biotech will pay $40 million upfront for the option to license TRPH-395, while committing to an additional $940 million or more in future R&D and sales milestone payments to Triphase Accelerator, a drug development company that looks to bring the compound through phase 2 proof of concept. Discovered by the Ontario Institute for Cancer Research (OICR), TRPH-395 aims to inhibit interactions with the WDR5 protein, to induce wider epigenetic modification of histones and disrupt the histone methylation that can support different cancers. But this isn’t Celgene’s first deal with Triphase. In November 2016, it acquired the accelerator’s proteasome inhibitor marizomib, which is currently being developed in brain cancer, for an undisclosed sum and maintains an ongoing partnership. Triphase has been supporting its clinical development, including a phase 2 study in recurrent glioma and a phase 1 study in newly diagnosed glioma, while marizomib is also being evaluated by Celgene in a phase 3 combination trial with Temodar and radiotherapy in late-stage malignant glioblastoma.